Landmark Agreements Strengthen Local Manufacturing and Stimulate Investment in Nigeria's Pharmaceutical Ecosystem

Strategic Insights -

The Federal Government, in partnership with the European Union (EU) and the Economic Community of West African States (ECOWAS), has signed three landmark agreements to strengthen local manufacturing and stimulate investment across the pharmaceutical ecosystem in Nigeria and West Africa. These agreements, part of the EU Global Gateway Manufacturing and Access to Vaccines, Medicines, and Health Technologies (MAV+) initiative and SRHR flagships, will support a new generation of local producers and innovators. The agreements aim to build a stronger and more resilient health ecosystem across Nigeria and the West African region.

Key Takeaways:

  • The agreements include Enabling Local Manufacturing of Health, Immunisation and Nutrition Commodities in Nigeria (ELM-N); Quality Uplift for Advancing Local Industry in Medicine Standards (Qualimeds Nigeria); and Strengthening Reproductive Health and Rights (SRHR) in West Africa.
  • The Vice President of Nigeria, Kashim Shettima, noted that the signing of the agreements reaffirms the Federal Government's resolve to build a sustainable, inclusive, and innovation-driven health economy.
  • Shettima emphasized the importance of creating an enabling environment for investors and innovators through predictable regulations, strong institutions, and public-private collaborations.
  • The EU Ambassador to Nigeria and ECOWAS, Gautier Mignot, stated that the forum demonstrates Team Europe's shared commitment to improving health across borders through strategic investments.
  • The EU has supported Nigeria through various health programs, including reproductive health and maternal and child health, with a current project funded by Agence Francaise de Developpement (AFD) and the Gates Foundation worth £45 million in Nigeria and £25 million in West Africa.
  • The Minister of Budget and Economic Planning, Senator Abubakar Bagudu, highlighted the potential for mutual prosperity and mutual gain between the EU and Nigeria in the health industry.
  • Nigeria's commitment to local production is anchored on three pillars: strengthening local production of health and pharmaceutical products; expanding access to essential medicines and vaccines; and advancing sexual and reproductive health rights.

Statistics:

  • The agreements are part of the EU Global Gateway Manufacturing and Access to Vaccines, Medicines, and Health Technologies (MAV+) initiative and SRHR flagships.
  • The EU has a £45 million project in Nigeria and £25 million in West Africa, funded by Agence Francaise de Developpement (AFD) and the Gates Foundation.
  • Nigeria's Renewed Hope Health Agenda aims to strengthen local production of health commodities, expand access to essential medicines and vaccines, and advance sexual and reproductive health rights.

Sources:

  • Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC)
  • National Institute for Pharmaceutical Research and Development (NIPRD)
  • European Union (EU)
  • Economic Community of West African States (ECOWAS)
  • Agence Francaise de Developpement (AFD)
  • Gates Foundation